Leander J D, Parli C J, Potts B, Lodge D
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
Epilepsia. 1992 Jul-Aug;33(4):696-704. doi: 10.1111/j.1528-1157.1992.tb02350.x.
Ameltolide, a newly described anticonvulsant, was studied to determine the relation between dose administered, plasma and brain concentrations, and pharmacologic effects. The relation of the N-acetyl metabolite and the OH-N-acetyl metabolite to the dose administered and to the pharmacologic effects was also determined. Ameltolide plasma concentrations in both mice and rats were linearly related to dose administered over the entire dose range from low doses, at which the anticonvulsant effects were noted, to high doses, at which neurologic impairment occurred. The plasma concentrations of the metabolites were not as consistently linearly dose-related in the two species. In rats, the brain concentrations of ameltolide were highly correlated with plasma concentrations and the doses administered. Ameltolide was shown to have a phenytoin (PHT)-like anticonvulsant profile in vitro in the cortical slice preparation. These data confirm the potent anticonvulsant profile of ameltolide and the lack of significant activity of the metabolites.
对新描述的抗惊厥药阿美妥利进行了研究,以确定给药剂量、血浆和脑内浓度与药理作用之间的关系。还确定了N-乙酰代谢物和OH-N-乙酰代谢物与给药剂量及药理作用之间的关系。在小鼠和大鼠中,阿美妥利的血浆浓度在整个剂量范围内(从出现抗惊厥作用的低剂量到出现神经功能损害的高剂量)均与给药剂量呈线性关系。在这两个物种中,代谢物的血浆浓度与剂量的线性关系并不一致。在大鼠中,阿美妥利的脑内浓度与血浆浓度及给药剂量高度相关。在体外皮质切片制备中,阿美妥利显示出类似苯妥英(PHT)的抗惊厥特征。这些数据证实了阿美妥利强大的抗惊厥特征以及代谢物缺乏显著活性。